Drug Profile
Research programme: CCRL2 antagonists - Oxagen
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Oxagen
- Class Small molecules
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergy in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in United Kingdom
- 30 Jun 2006 Preclinical trials in Allergy in United Kingdom (unspecified route)